Mammoth is transitioning from a diagnostics-focused company toward therapeutic CRISPR applications, targeting permanent genetic cures through partnerships with major pharmaceutical firms like Regeneron (partnership announced April 2024). With lead drug candidate MB-111 designated in May 2025, the company aims to establish itself as a foundational platform provider in the genomics era, leveraging its strong IP from Doudna and early-stage partnerships with leading biotech and pharma companies.
Cyborg Score Rationale
Mammoth demonstrates strong fundamentals with $375M total funding, $1B unicorn valuation (as of September 2021), backing from top-tier VCs (Mayfield, NFX, Redmile Group), and strategic partnerships with Regeneron. However, the company remains private, pre-approval on lead therapeutics, and faces intense CRISPR competition. The lack of recent funding announcements post-April 2024 and absence of revenue disclosure suggest execution risk ahead.
Top Insights
Transitioning from diagnostics to therapeutics: Mammoth is shifting strategic focus from CRISPR-based disease detection (DETECTR platform) to gene editing therapeutics, with MB-111 as lead candidate as of May 2025
Ultra-compact CRISPR IP advantage: The company's proprietary NanoCas and CasPhi systems enable smaller, more deliverable CRISPR enzymes compared to standard Cas9, addressing a major limitation in in vivo gene therapy
Pharma validation: Regeneron partnership (April 2024) for next-generation CRISPR gene editing across multiple disease indications signals institutional validation and revenue diversification beyond diagnostics
Scientific pedigree and board strength: Co-founded by Jennifer Doudna (CRISPR Nobel laureate) with board appointments of pharma veterans (Bob Brown, May 2025) and backing from Tim Cook and Jeff Huber early-stage, demonstrating access to capital and networks
Named Competitors
Editas Medicine — CRISPR-based therapeutics for inherited retinal disease and other genetic disorders